skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

UK_Brexit_Pharma_Intelligence

With less than three months to go before the UK is due to leave the EU, manufacturers based in any of the EU 27 countries (i.e, all of the EU countries not including the UK) are still finding it difficult to get their heads around the new demands that could be placed on them to continue marketing products in the UK in the event of a no-deal Brexit.

Terms of the UK leaving the EU have still not been agreed, and the scenario of no deal being reached between the EU and UK is looking increasingly likely. Internally, divided UK factions struggle to find any kind of agreement.

More from MHRA

For more details about the MHRA registration deadlines in the event of a no-deal Brexit see: Brexit At The 11th Hour: UK Refreshes No-Deal Guidance For Medtech

One of the requirements, as explained in the government's Jan. 3 document, "Further guidance note on the regulation of medicines, medical devices and clinical trials if there's no Brexit deal,"will be for EU 27 manufacturers to have a "Responsible Person" based in the UK. The responsibilities of this person will be similar to those of the European Authorized Representative under the EU medical device rules.

The guidance note, published by the UK Medicines and Healthcare products Regulatory Agency (MHRA), states that where a device manufacturer is not established in the UK, "registration of a product with the MHRA must be undertaken by a ‘UK Responsible Person’ established in the UK and with a UK registered address who will take responsibility for the product in the UK."

But there are still questions being voiced in industry over whether this ‘UK Responsible Person’ needs to be physically present in the UK. In response, the MHRA has told Medtech Insight that "there would need to be someone physically located within the UK."

The agency's full statement reads: “Whilst the UK Responsible Person may make use of resources based outside of the UK, there would need to be someone physically located within the UK for the MHRA to communicate with and they must provide an address which can be used for official communications. The UK Responsible Person must be contactable at the address provided and is obliged to keep certain information at the disposal of the MHRA, such as declarations of conformity and technical documentation."

EU Position

It is also worth pointing out that the European Commission made it clear in a  January 2018 notice to stakeholders that, under a no-deal scenario, businesses with an authorized representative based in the UK would need to establish a new authorized representative in an EU country if the companies want an representative to carry out tasks on their behalf within the EU.

From the editors of Clinica

 

Read also

  • In Vivo: strategic insights for life sciences decision-maker...

    Pharma News and Healthcare Business Insights

    <p><span>Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare &amp; biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.</span></p>

  • Medtech Insight: global medical technology news & analysis

    UK Notified Body BSI Sets Out Clear Post-Brexit Paths As It Goes Dutch

    BSI tackles Brexit issues head-on with aim to allay fears and bring clarity while UK regulator, MHRA, remains reticent to do so. Its messages are relevant for all doing business in the UK

    Topics Brexit

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: